InBody vs OMRON Which Should You Buy?

InBody and OMRON are two prominent companies in the health and wellness sector, each specializing in innovative products designed to help individuals in tracking their fitness and health goals. InBody focuses on body composition analysis technology, while OMRON is known for its range of health monitoring devices such as blood pressure monitors and fitness trackers. Both companies have seen impressive growth in recent years, making their stocks highly attractive to investors seeking exposure to the growing health and wellness market.

InBody or OMRON?

When comparing InBody and OMRON, different investors may prioritize various metrics based on their investment strategies and goals. So, ask yourself what type of investor you are. This will guide you in determining which metrics are most important for your investment decision between InBody and OMRON.

Dividend Investors:

Dividend investors look for stable and growing income streams, using dividend metrics to assess potential investments. A company's dividend yield essentially measures the size of its dividend relative to the total market value of the company. InBody has a dividend yield of 1.3%, while OMRON has a dividend yield of 2.1%. Beyond the yield itself, considering the growth and sustainability of these dividends is also crucial. InBody reports a 5-year dividend growth of 0.00% year and a payout ratio of 14.33%. On the other hand, OMRON reports a 5-year dividend growth of -0.62% year and a payout ratio of -134.14%.

Value Investors:

Value investors focus on financial metrics to determine a stock's intrinsic value compared to its market value. The Price-to-Earnings (P/E) Ratio links stock price to a company's earnings per share, with InBody P/E ratio at 9.46 and OMRON's P/E ratio at -64.30. Another crucial valuation metric is the Price-to-Book (P/B) Ratio, which compares stock price with book value per share. InBody P/B ratio is 1.12 while OMRON's P/B ratio is 1.19.

Growth Investors:

Growth investors prioritize metrics indicative of a company's expansion potential. Focusing on top-line growth, InBody has seen a 5-year revenue growth of 0.77%, while OMRON's is 0.09%. Return on Equity (ROE) measures how effectively a company uses equity investment to generate earnings, with InBody's ROE at 12.30% and OMRON's ROE at -1.92%.

Retail Investors:

Retail investors often consider stock affordability and company familiarity. For example, day low prices are ₩22350.00 for InBody and $31.68 for OMRON. Over the past year, InBody's prices ranged from ₩20700.00 to ₩30700.00, with a yearly change of 48.31%. OMRON's prices fluctuated between $31.00 and $47.89, with a yearly change of 54.48%. Brand recognition also plays a role, as familiarity with a company can influence investment decisions.